CTLA4 and hepatocellular carcinoma: Tremelimumab is the first CTLA‐4 inhibitor for HCC, and has relatively safety and antitumor efficacy in patients with advanced liver cancer and chronic HCV infection (ClinicalTrials.gov, NCT01008358).17